Capricor Plunges 14.84% on Mid-Cycle Review

Generado por agente de IAAinvest Movers Radar
lunes, 5 de mayo de 2025, 8:26 am ET1 min de lectura
CAPR--

On May 5, 2025, Capricor's stock experienced a significant drop of 14.84% in pre-market trading, reflecting a notable decline in investor sentiment.

Capricor Therapeutics recently announced the completion of its mid-cycle review, a critical milestone in its ongoing clinical trials. This development is part of the company's broader strategy to advance its therapeutic pipeline and bring innovative treatments to market.

Additionally, CapricorCAPR-- reported its Q3 2024 earnings, posting a revenue of $2.3 million. While this figure may not be groundbreaking, it underscores the company's efforts to generate revenue through its existing products and services, providing a foundation for future growth.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios